Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ropidoxuridine · NSC-726188

Small molecule · Acts on DNA · developed by Shuttle Pharmaceuticals

Phase 2 Most advanced trial (none active)

SHPH Developer

1 Registered trials

What is Ropidoxuridine?

Ropidoxuridine is an orally available prodrug of iododeoxyuridine that is converted hepatically to its active form. It incorporates into DNA during replication to sensitize cells to ionizing radiation by increasing DNA strand breaks. It is studied in glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: NSC-726188, 5-iodo-2-pyrimidinone-2'-deoxyribose
Drug type: Small molecule
Targets: DNA
Mechanism: Acts on DNA
Pathways: DNA strand breaks, radiosensitization
Therapy area: Oncology
Developer: Shuttle Pharmaceuticals, Inc. (SHPH)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 3HX21A3SQF

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06359379	Phase 2	Glioblastoma, IDH-wildtype	Terminated	SHPH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma, IDH-wildtype

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the SHPH page.

Follow SHPH, the company behind Ropidoxuridine

See SHPH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SHPH catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z